Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.

Antiviral research - 1 Sept 1994

Dewindt B, van Eemeren K, Andries K

Abstract excerpt

The effect of four structurally diverse capsid-binding compounds on the adsorption of seven human rhinoviruses (HRV), representative for both receptor and antiviral groupings was studied using infective center assays. Antiviral compounds studied included a pyridazinamine (R 61837), an isoxazole (WIN 51711), a flavan (4',6-dichloroflavan) and a chalcone (Ro-09410). Minor receptor viruses studied were HRV 1A, HRV 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adsorption
Share to Antiviral Agents
Share to Capsid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Flavonoids

Share to HeLa Cells

Share to Mutation

Share to Protein Conformation

Share to Receptors, Virus

Source

Identifiers

PMID: 7811059
DOI: 10.1016/0166-3542(94)90094-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.PMID 7811059Read ↗

Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicitySemantic proximity Read ↗

The human rhinovirus: human‐pathological impact, mechanisms of antirhinoviral agents, and strategies for their discoverySemantic proximity Read ↗

VP1 Sequencing of All Human Rhinovirus Serotypes:Insights into Genus Phylogeny and Susceptibility to AntiviralCapsid-BindingCompoundsSemantic proximity Read ↗

Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domainsSemantic proximity Read ↗

Rhinoviral receptor discrimination: mutational changes in the canyon regions of human rhinovirus types 2 and 14 indicate a different site of interaction.Semantic proximity Read ↗

X-ray structure of a minor group human rhinovirus bound to a fragment of its cellular receptor proteinSemantic proximity Read ↗

WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.Semantic proximity Read ↗

Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyonSemantic proximity Read ↗

Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.Semantic proximity Read ↗

Structural studies on human rhinovirus 14 drug-resistant compensation mutants.Semantic proximity Read ↗

Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.